株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の生物製剤医薬品受託製造開発機関企業 (CDMO) 市場予測:2022年

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022

発行 Frost & Sullivan 商品コード 712901
出版日 ページ情報 英文 93 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.17円で換算しております。
Back to Top
世界の生物製剤医薬品受託製造開発機関企業 (CDMO) 市場予測:2022年 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022
出版日: 2018年09月19日 ページ情報: 英文 93 Pages
概要

世界の医薬品産業は、病気をめぐる状況の変化において新たな治療法のニーズに高まりとともに進化しています。増加する慢性感染症の罹患率および癌発生率の増加を受け、市場ニーズは従来型の小分子から大分子へと移行しています。

当レポートでは、世界における生物製剤医薬品受託製造開発機関企業 (CDMO) の状況について、世界の生物製剤アウトソーシング市場における主な動向と成長機会に注目して分析しており、市場の成長展望と成長率、急成長セグメント、成長機会、主な成長促進要因・抑制要因、主な課題、革新的企業などについてまとめています。

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場概要
  • 定義
  • 医薬品アウトソーシングのバリューチェーン
  • 市場区分
  • 世界市場の展望
  • マクロ動向:生物製剤開発・製造
  • 技術動向:バイオロジクス開発・製造
  • 新興のCDMOビジネスモデル
  • ビジネスモデルの変化:バーチャルファーマの増加
  • バーチャルファーマ:医薬品会社・バイオテクノロジーアウトソーシングエコシステムにおける市場の変化
  • アウトソーシングによって可能となるバーチャルバイオテクノロジー企業

第3章 競合プレイブック

  • 革新的な生物製剤CDMO企業
  • 新しい市場機会
  • 競合情勢のスナップショット
  • 競合プレイブック:市場シェア分析

第4章 促進要因・抑制要因・動向:生物製剤CDMO市場全体

  • 市場成長促進要因
  • 市場成長抑制要因
  • 生物製剤CDMO市場の参入障壁
  • 世界のCDMO市場:主な動向
  • 生物製剤CDMO市場にわたる破壊的技術の動向
  • ステンレススチールバイオリアクターに勝る使い捨てのメリット
  • スングルユース/使い捨ておよび従来型大容量ステンレススチールバイオリアクターの比較
  • CDMO:技術別
  • 哺乳類 vs. 微生物細胞培養の比較分析

第5章 予測・動向:生物製剤CDMO市場全体

  • 市場エンジニアリング測定
  • 予測の前提条件
  • 収益予測
  • 収益予測の議論
  • CDMOアウトソーシングの可能性
  • アウトソーシングの動向・論拠
  • 高いアウトソーシング浸透率

第6章 セグメントの分析:予測・動向

  • 収益予測:サービスタイプ別
  • 収益比予測:サービスタイプ別
  • 収益予測の議論:サービスタイプ別
  • 収益予測:細胞培養タイプ別
  • 収益比予測:細胞培養タイプ別
  • 収益予測の議論:細胞培養タイプ別

第7章 成長機会・CTA (行動喚起)

  • 産業エコシステムにおける転換
  • 5つの主な成長機会
  • 成長機会1:製造におけるIIoT
  • 成長機会2:デザイナー細胞株
  • 成長機会3:バイオシミラーの共同開発
  • 成長機会4:シングルユース/使い捨て製造
  • 成長機会5:生物学的開発 & サービス
  • 成功・成長の戦略インペラティブ

第8章 顧客・エンドユーザー分析

  • CDMOの選定に影響する主な特徴
  • CDMO選定要因の重要性:公表済み vs. 未公表
  • CDMO選定要因の重要性の議論:公表済み vs. 未公表

第9章 結論

第10章 付録

目次
Product Code: MC9B-52

Investments in Single Use/Disposable Technologies to Capitalize on Growth Opportunities in High-value Low-volume Biologics

The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global biologics Contract Development and Manufacturing Organization (CDMO) landscape with an emphasis on the key trends and growth opportunities across the global biologics outsourcing market. It also highlights the shifting focus and investments of pharma/biotech participants toward BioCDMOs for innovative biologics discovery, development, and manufacturing.

With the changing market landscape, BioCDMOs are shifting toward providing value-added services by establishing themselves as a one-stop-shop for their pharma clients. These companies are adopting advanced manufacturing technologies such as single-use/disposable bioreactors, continuous, POD manufacturing, and so on with the integration of IT-based solutions implementing the Industrial Internet of Things (IIoT) by means of strategic collaborations and partnerships. Larger participants are resorting to Mergers and Acquisitions (M&As) in order to gain specific therapeutic and technical expertise from smaller, niche BioCDMOs. While the US and Europe are key markets, the outsourcing trend is slowly shifting toward APAC with several new entrants providing cost-effective drug development services.

Research Scope

The study aims at identifying some key growth opportunities such as biosimilars co-development, designer cell lines, bioanalytical development and services, and so on that are set to drive the market over the next 5 years. It provides revenue forecasts of the global BioCDMO market as well as a breakdown by type of cell culture (mammalian versus microbial) and service type (drug substance verus drug product). The study highlights some of the key market drivers and restraints that will affect the overall growth of the market. Additionally, it provides an insight into leading disruptive technology trends such as improvements in upstream and downstream technologies, advances in lyophilisation, and increased application of Process Analytical Technologies (PAT) that are shaping the future of the BioCDMO industry. The study also highlights some emerging business models such as expanding services of CMOs into early stage of drugs, emergence of virtual biotech, out-licensing, and risk sharing between pharma and CMOs that are disrupting traditional business models.

Key Issues Addressed

  • Is the biologic contract manufacturing market growing, how long will it continue to grow and at what rate?
  • What are the fastest growing segments of the biologics contract development and manufacturing market?
  • What growth opportunities exist in the biologics contract development and manufacturing industry?
  • What are the key drivers and restraints affecting the growth of CDMOs?
  • What are the key challenges that CDMOs are likely to face in the near and long-term future? How can CDMOs strategize to overcome these hurdles?
  • In what ways is the biologics contract manufacturing industry likely to change to meet industry trends and dynamics?
  • Which are the game-changing companies and what are the disruptive technologies and business models? How do CDMOs position their assets with pharma companies?

Table of Contents

1. EXECUTIVE SUMMARY

  • Key Findings
  • Scope and Segmentation
  • Key Questions This Study Will Answer
  • Market Engineering Measurements
  • CEO's Perspective
  • 8 Big Market Themes for BioCDMO Market
  • Defining Trends in the Biologics CDMO Market
  • Executive Summary-3 Big Predictions

2. MARKET OVERVIEW

  • Market Overview
  • Definitions
  • Pharmaceutical Outsourcing Value Chain
  • Market Segmentation
  • Global Market Perspective
  • Macro Trends-Biologics Development and Manufacturing
  • Technology Trends-Biologics Development and Manufacturing
  • Emerging CDMO Business Model
  • Emerging CDMO Business Model (continued)
  • Emerging CDMO Business Model (continued)
  • Changing Business Model-Rise in Virtual Pharma
  • Virtual Pharma-Change Makers in the Pharma and Biotech Outsourcing Ecosystem
  • Virtual Biotech Companies Enabled by Outsourcing

3. COMPETITIVE PLAYBOOK

  • Game-changing BioCDMO Companies
  • New Market Opportunities
  • New Market Opportunities (continued)
  • New Market Opportunities (continued)
  • Snapshot of Competitive Landscape
  • Competitive Playbook-Market Share Analysis

4. DRIVERS, RESTRAINTS AND TRENDS-TOTAL BIOCDMO MARKET

  • Market Drivers
  • Market Restraints
  • Entry Barriers of Biologics CDMO Markets
  • Entry Barriers of Biologics CDMO Markets (continued)
  • Global CDMO Market-Key Trends
  • Global CDMO Market-Key Trends (continued)
  • Disruptive Technology Trends Across the BioCDMO Market
  • Benefits of Disposable Over Stainless Steel Bioreactors
  • Comparative Analysis of Single-use/Disposable and Traditional Large-capacity Stainless Steel Bioreactors
  • Comparative Analysis of Perfusion and Batch Manufacturing
  • CDMO by Technology
  • Comparative Analysis of Mammalian Versus Microbial Cell Culturing

5. FORECAST AND TRENDS-TOTAL BIOCDMO MARKET

  • Market Engineering Measurements
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast Discussion
  • CDMO Outsourcing Potential
  • Outsourcing Trends and Rationale
  • Higher Outsourcing Penetration

6. SEGMENT ANALYSIS-FORECAST AND TRENDS

  • Revenue Forecast by Service Type
  • Percent Revenue Forecast by Service Type
  • Revenue Forecast Discussion by Service Type
  • Revenue Forecast by Cell Culture Type
  • Percent Revenue Forecast by Cell Culture Type
  • Revenue Forecast Discussion by Cell Culture Type

7. GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

  • Transformation in Industry Ecosystem
  • 5 Major Growth Opportunities
  • Growth Opportunity 1-IIoT in Manufacturing
  • Growth Opportunity 2-Designer Cell Lines
  • Growth Opportunity 3-Biosimilar Co-development
  • Growth Opportunity 4-Single-Use/Disposable Manufacturing
  • Growth Opportunity 5-Bioanalytical Development & Services
  • Strategic Imperatives for Success and Growth

8. CUSTOMER AND END-USER ANALYSIS

  • Key Characteristics Influencing CDMO Selection
  • Stated Versus Unstated Importance of CDMO Selection Factors
  • Stated Versus Unstated Importance of CDMO Selection Factors Discussion

9. THE LAST WORD

  • The Last Word-3 Big Predictions
  • Legal Disclaimer

10. APPENDIX

  • Drivers Explained
  • Drivers Explained (continued)
  • Drivers Explained (continued)
  • Restraints Explained
  • Restraints Explained (continued)
  • Restraints Explained (continued)
  • Market Engineering Methodology
  • List of Vendors Included in this Research
  • List of Exhibits
  • List of Exhibits (continued)
Back to Top